Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Complement proteins in cerebrospinal fluid: New biomarkers of pre-symptomatic Alzheimer's disease and dementia progression

FY 2023-24

Summary
In the brain, the immune complement system eliminates redundant neural connections in a process called synaptic pruning. In neurodegenerative diseases such as Alzheimer's disease (AD), this system is believed to inappropriately over-prune synapses, leading to brain atrophy and cognitive impairment. While increased cerebrospinal fluid (CSF) levels of complement proteins have been observed in clinical AD patients, no studies have yet investigated the role of complement in the pre-symptomatic phase of AD, nor throughout AD progression. I propose that the complement system is involved in the pre-symptomatic phase of AD and throughout AD progression via excessive synaptic pruning. I hypothesize that increased CSF levels of complement proteins are associated with biomarkers of AD and synaptic damage, decreased cortical volume and thickness, and reduced cognitive performance. I also predict that complement levels change throughout disease progression, with asymptomatic individuals exhibiting different CSF complement levels than mild cognitive impairment (MCI) and clinical AD patients. I will use immunoassay technology to measure CSF complement protein levels in high-risk asymptomatic (neurologically normal controls with parental history of AD) and symptomatic (MCI and AD) individuals. Complement levels will be correlated with CSF biomarkers of AD pathology (amyloid and tau) and synaptic damage; PET scans visualizing cerebral deposition of amyloid and tau; MRI scans measuring volume of AD-implicated brain structures (hippocampus, entorhinal cortex, and lateral ventricles); and cognitive measures assessing memory, language, attention, and visuospatial ability. Sex, education, and APOE genotype will also be recorded to examine effects moderating the complement-AD relationship.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506481
Name
Loncke Julia M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Complement proteins in cerebrospinal fluid: New biomarkers of pre-symptomatic Alzheimer's disease and dementia progression
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Apoe; Cerebrospinal Fluid Biomarkers; Complement System; Neurodegeneration; Pre-Symptomatic Phase; Synaptic Pruning
Abstract
In the brain, the immune complement system eliminates redundant neural connections in a process called synaptic pruning. In neurodegenerative diseases such as Alzheimer's disease (AD), this system is believed to inappropriately over-prune synapses, leading to brain atrophy and cognitive impairment. While increased cerebrospinal fluid (CSF) levels of complement proteins have been observed in clinical AD patients, no studies have yet investigated the role of complement in the pre-symptomatic phase of AD, nor throughout AD progression. I propose that the complement system is involved in the pre-symptomatic phase of AD and throughout AD progression via excessive synaptic pruning. I hypothesize that increased CSF levels of complement proteins are associated with biomarkers of AD and synaptic damage, decreased cortical volume and thickness, and reduced cognitive performance. I also predict that complement levels change throughout disease progression, with asymptomatic individuals exhibiting different CSF complement levels than mild cognitive impairment (MCI) and clinical AD patients. I will use immunoassay technology to measure CSF complement protein levels in high-risk asymptomatic (neurologically normal controls with parental history of AD) and symptomatic (MCI and AD) individuals. Complement levels will be correlated with CSF biomarkers of AD pathology (amyloid and tau) and synaptic damage; PET scans visualizing cerebral deposition of amyloid and tau; MRI scans measuring volume of AD-implicated brain structures (hippocampus, entorhinal cortex, and lateral ventricles); and cognitive measures assessing memory, language, attention, and visuospatial ability. Sex, education, and APOE genotype will also be recorded to examine effects moderating the complement-AD relationship.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Loncke, Julia M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~